Literature DB >> 24627592

Immune dysfunction in cirrhosis.

Nora Sipeki1, Peter Antal-Szalmas1, Peter L Lakatos1, Maria Papp1.   

Abstract

Innate and adaptive immune dysfunction, also referred to as cirrhosis-associated immune dysfunction syndrome, is a major component of cirrhosis, and plays a pivotal role in the pathogenesis of both the acute and chronic worsening of liver function. During the evolution of the disease, acute decompensation events associated with organ failure(s), so-called acute-on chronic liver failure, and chronic decompensation with progression of liver fibrosis and also development of disease specific complications, comprise distinct clinical entities with different immunopathology mechanisms. Enhanced bacterial translocation associated with systemic endotoxemia and increased occurrence of systemic bacterial infections have substantial impacts on both clinical situations. Acute and chronic exposure to bacteria and/or their products, however, can result in variable clinical consequences. The immune status of patients is not constant during the illness; consequently, alterations of the balance between pro- and anti-inflammatory processes result in very different dynamic courses. In this review we give a detailed overview of acquired immune dysfunction and its consequences for cirrhosis. We demonstrate the substantial influence of inherited innate immune dysfunction on acute and chronic inflammatory processes in cirrhosis caused by the pre-existing acquired immune dysfunction with limited compensatory mechanisms. Moreover, we highlight the current facts and future perspectives of how the assessment of immune dysfunction can assist clinicians in everyday practical decision-making when establishing treatment and care strategies for the patients with end-stage liver disease. Early and efficient recognition of inappropriate performance of the immune system is essential for overcoming complications, delaying progression and reducing mortality.

Entities:  

Keywords:  Cirrhosis; Endotoxemia; Immune dysfunction

Mesh:

Substances:

Year:  2014        PMID: 24627592      PMCID: PMC3949265          DOI: 10.3748/wjg.v20.i10.2564

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  143 in total

Review 1.  Role of Toll-like receptor impairment in cirrhosis infection risk: are we making progress?

Authors:  Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Mário Dinis-Ribeiro; Adelino F Leite-Moreira
Journal:  Liver Int       Date:  2010-09-02       Impact factor: 5.828

2.  Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.

Authors:  H Grønbaek; T D Sandahl; C Mortensen; H Vilstrup; H J Møller; S Møller
Journal:  Aliment Pharmacol Ther       Date:  2012-05-16       Impact factor: 8.171

Review 3.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

Review 4.  Infectious complications of acute and chronic liver disease.

Authors:  Bettina Leber; Walter Spindelboeck; Vanessa Stadlbauer
Journal:  Semin Respir Crit Care Med       Date:  2012-03-23       Impact factor: 3.119

5.  Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria.

Authors:  N Hiki; D Berger; C Prigl; E Boelke; H Wiedeck; M Seidelmann; L Staib; M Kaminishi; T Oohara; H G Beger
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

6.  Antibodies to intestinal microbes in serum of patients with cirrhosis of the liver.

Authors:  M Bjorneboe; H Prytz; F Orskov
Journal:  Lancet       Date:  1972-01-08       Impact factor: 79.321

7.  High prevalence of antibodies to calreticulin of the IgA class in primary biliary cirrhosis: a possible role of gut-derived bacterial antigens in its aetiology?

Authors:  W Kreisel; A Siegel; A Bahler; C Spamer; E Schiltz; M Kist; G Seilnacht; R Klein; P A Berg; C Heilmann
Journal:  Scand J Gastroenterol       Date:  1999-06       Impact factor: 2.423

8.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

9.  Ammonia impairs neutrophil phagocytic function in liver disease.

Authors:  Debbie L Shawcross; Gavin A K Wright; Vanessa Stadlbauer; Stephen J Hodges; Nathan A Davies; Caroline Wheeler-Jones; Andrew A Pitsillides; Rajiv Jalan
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

10.  Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation.

Authors:  B Massonnet; A Delwail; J-M Ayrault; C Chagneau-Derrode; J-C Lecron; C Silvain
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

View more
  56 in total

Review 1.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

2.  Renal and Gastrointestinal Considerations in Joint Replacement Surgery.

Authors:  Benjamin Voss; Alexander Kurdi; Alexander Skopec; Jasmine Saleh; Mouhanad M El-Othmani; Joseph M Lane; William M Mihalko; Khaled J Saleh
Journal:  J Nat Sci       Date:  2015-02-01

3.  Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.

Authors:  Mohamad A Mouchli; Siddharth Singh; Edward V Loftus; Lisa Boardman; Jayant Talwalkar; Charles B Rosen; Julie K Heimbach; Russell H Wiesner; Bashar Hasan; John J Poterucha; Watt D Kymberly
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

Review 4.  Bloodstream infections in patients with liver cirrhosis.

Authors:  Michele Bartoletti; Maddalena Giannella; Russell Edward Lewis; Pierluigi Viale
Journal:  Virulence       Date:  2016-02-11       Impact factor: 5.882

5.  Tuberculosis after liver transplantation in a large center in New York City: QuantiFERON® -TB Gold-based pre-transplant screening performance and active tuberculosis post-transplant.

Authors:  Jonathan Hand; Keith Sigel; Shirish Huprikar; Camille Hamula; Meena Rana
Journal:  Transpl Infect Dis       Date:  2018-02-19       Impact factor: 2.228

Review 6.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 7.  Influence of cirrhosis in cardiac surgery outcomes.

Authors:  Juan C Lopez-Delgado; Francisco Esteve; Casimiro Javierre; Josep L Ventura; Rafael Mañez; Elisabet Farrero; Herminia Torrado; David Rodríguez-Castro; Maria L Carrio
Journal:  World J Hepatol       Date:  2015-04-18

Review 8.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 9.  Outcomes of abdominal surgery in patients with liver cirrhosis.

Authors:  Juan C Lopez-Delgado; Josep Ballus; Francisco Esteve; Nelson L Betancur-Zambrano; Vicente Corral-Velez; Rafael Mañez; Antoni J Betbese; Joan A Roncal; Casimiro Javierre
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

10.  Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis.

Authors:  Melisa Dirchwolf; Andrés Eduardo Ruf
Journal:  World J Hepatol       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.